

Haematologica
HAEMATOL/2020/255620
Version 4

Treatment with emapalumab in an ADA-SCID patient with refractory
hemophagocytic lymphohistiocytosis-related graft failure and
disseminated BCGitis

Francesca Tucci, Vera Gallo, Federica Barzaghi, Francesca Ferrua,
Maddalena Migliavacca, Valeria Calbi, Matteo Doglio, Elena Sophia
Fratini, Zeynep Karakas, Sukru Guner, Matilde Zambelli, Cristina Parisi,
Raffaella Milani, Salvatore Gattillo, Benedetta Mazzi, Chiara Oltolini,
Maurizio Barbera, Cristina Baldoli, Daniela Maria Cirillo, Veronica
Asnaghi, Cristina De Min, Maria Pia Cicalese, Fabio Ciceri, Alessandro
Aiuti, and Maria Ester Bernardo

Disclosures: Disclosure of conflict of interest: MPC is PI of the long-term follow up study sponsored by Orchard Therapeutics for patients treated with Strimvelis and AA is PI of clinical trials sponsored by Orchard Therapeutics. VA is an employee of Sobi; CdM is consultant for Sobi

Contributions: Contribution: FT, VG followed the clinical course of the patient, collected data, analyzed results and wrote the paper; FB, FF, MM, VC, MD, MPC, ESF, CO followed the clinical course of the patient and collected data; ZK and SG followed the patient before referral to our Institution; SG collected peripheral blood hematopoietic stem cells from the donors; MZ, CP and RM performed graft manipulation; BM performed chimerism analyses; CB and MB performed radiological evaluations; DMC performed fecal PCR for detection of Mycobacterium bovis; VA and CDM provided emapalumab as per CU, performed PK/PD emapalumab evaluations, critically read the manuscript and helped with scientific discussion; AA and FC critically revised the manuscript and helped with scientific discussion; MEB advised on the design the study, analyzed data and contributed to the final writing of the paper.